Ebba BRAKENHIELM PhD Tumor Biology, Habilitus Cardiac Pathophysiology

Course and current status

PROFESSIONAL EXPERIENCE______________________

2012-present:    Tenured researcher (chargé de recherché Inserm, CR1) in the group of Dr Vincent Richard at Inserm U1096, Rouen Institute for Research and Innovation in Biomedicine, University of Rouen, France

Research topic:Development of novel biotherapies for heart failure

2007-2011:        Tenured research associate in the group of Pr. Christian Thuillez at the Inserm U644, U.F.R de Médecine-Pharmacie, University of Rouen, France

Research topic:Development of novel therapeutic strategies to stimulate revascularization with focus on myocardial ischemia and heart failure

2005-2006:        Postdoctoral fellow in the group of Pr. Christian Thuillez at the Inserm U644, U.F.R de Médecine-Pharmacie, University of Rouen, France

Research topic: “Role of vasculogenesis in cardiovascular diseases and studies of cell therapy during ischemic remodeling”


2004-2005:          Postdoctoral researcher in Pr. Lily Wu’s group at the MRL Research Laboratories, David Geffen School of Medicine, UCLA, Los Angeles, USA

Project: “Use of molecular imaging to investigate tumor lymphangiogenesis and metastasis in prostate and breast cancer”


2003-2004:         Research associate in Pr. Yihai Cao’s group at the Microbiology and Tumor Biology Center, Karolinska Institutet, Stockholm, Sweden

Projects: “Angiogenesis inhibitors in obesity” and “Identification of novel angiogenesis inhibitors from adipose tissue”


EDUCATION & DEGREES_______________________

2012:                     Dr Habil degree in Physiology at the Rouen University 

2003:                     Ph.D degree in Tumor Biology at the Karolinska Institutet in Pr. Yihai Cao’s group with a thesis entitled “Angiogenesis in Obesity and Cancer”.

1997-1999:           Undergraduate studies of Human Physiology, Neurobiology and Neuropsychology at the Karolinska Institutet, Stockholm, Sweden. 

1998:                     Master of Science degree in Chemistry at the University of Stockholm, Sweden. Exam project work in Dr. Ulo Langel’s laboratory at the department of Neurochemistry with a thesis entitled “Novel Cell-Penetrating Peptides”.

Scientific summary

Initially trained at Stockholm University in Sweden as chemist, specializing in neurochemistry and cell-penetrating peptides for delivery of therapeutic molecules, I opted for a PhD thesis (1999-2003) in biology at Karolinska Institutet working in the laboratory of Pr Yihai Cao. The thematic of my research work was “Discovery and Characterization of Novel Angiogenesis Inhibitors in pathophysiology”, including evaluation of the impact of anti-angiogenic treatments both in the setting of tumor models and in adipose tissue expansion using mouse models of obesity. Further, as a side project, I also participated in studies of therapeutic angiogenesis for ischemic diseases.

I pursued my postdoctoral studies at UCLA, California, in the laboratory of Pr. Lily Wu, focusing on molecular imaging of tumor metastasis and the impact of tumor lymphangiogenesis.

Since 2005 I have been working as a full-time researcher in a cardiovascular research laboratory, Inserm U1096, in Rouen (Normandy region) in France, where I’m currently directing a small team of undergraduate and graduate students as well as a research engineer. Together, we have been investigating the impact of therapeutic stimulation of blood and lymphatic vessel growth in cardiovascular diseases, in particular chronic heart failure.

My most important research contributions include:

  • Henri O, ..., Brakenhielm ESelective Stimulation of Cardiac Lymphangiogenesis Reduces Myocardial Edema and Fibrosis Leading to Improved Cardiac Function Following Myocardial Infarction  Circulation 2016 133(15):1484-97 
  • Banquet S,... Brakenhielm E   Arteriogenic therapy by intramyocardial sustained delivery of a novel growth factor combination prevents chronic heart failure. Circulation 2011 124:1059-1069                                                     (cited 26 times)
  • Nissen LJ, Cao R, .... Brakenhielm E, and Cao Y  Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis. J. Clin. Invest. 2007 117(10):2766-2777                                (cited 151 times)
  • Brakenhielm E, et al.  Angiogenesis inhibitor, TNP-470, prevents diet-induced and genetic obesity in mice. Circ Res. 2004 94(12):1579-1588.                (cited 137 times)
  • Brakenhielm E, et al.  Adiponectin-induced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci USA 2004 101(8):2476-2481    (cited 378 times)
  • Cao R, Brakenhielm E, et al.   Angiogenic synergism, vascular stability and improvement of hind limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003 9(5):604-613.                                                      (cited 367 times)
Image d’exemple